Rx Bandz, LLC — Department of Defense SBIR Phase I: AF211-CSO1
Rx Bandz, LLC — SBIR Phase I award from Department of Defense.
- Amount
- $49,434
- Agency
- Department of Defense · Air Force
- Program / Phase
- SBIR · Phase I
- Topic
- AF211-CSO1
- Solicitation
- X21.1
- NAICS
- —
- Place of performance
- TX
- Period
- 2021-04-14 → 2021-07-19
Description
MiniJect™ is a versatile intramuscular (IM) auto-injector that is critically important when warfighters require medication, such as Tranexamic Acid (TXA), for excessive bleeding in combat or emergency situations. The DoD, following recommendations from the TCCC, has made a TXA auto-injector Priority #4, to replace current IV delivery. TXA is proven to stop excessive bleeding from battlefield trauma. It is delivered faster, more accurately and reliably intramuscularly (IM) than via intravenous (IV line/bag) which is suboptimal for the chaos on the battlefield. MiniJect™ is the size of a large thumb-drive and easily fits into a pocket or attaches to a belt. Its features - impact resistant, IR/UV-shielded, waterproof – are well suited to austere conditions, including deployed settings and outside the wire operations.